PD L1 News and Research

RSS

Manipulating macrophages could be a viable strategy for treating cancer

Most traditional cancer therapies target either the tumor cells themselves or indiscriminately kill any rapidly dividing cell.

22 Jun 2020

New combination of biomarkers can benefit patients with advanced bladder cancer

In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center.

18 Jun 2020

Novel immunotherapy-plus-chemotherapy combo for pleural mesothelioma shows promise

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

11 Jun 2020

Jane and Aatos Erkko Foundation awards 1.5 million euros to support breast cancer study

1.5 million euros funding supports a new investigator-initiated breast cancer clinical trial in Finland that takes on MYC.

11 Jun 2020

Novel immunotherapy targeting myeloid immune cells reduces tumor growth

Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions.

27 May 2020

Novel biomarkers linked to improved outcomes with immunotherapy in metastatic breast cancer

Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.

22 May 2020

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.

20 May 2020

Roswell Park team proposes possible new strategy for treating pancreatic cancer

A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology.

18 May 2020

Innovative approach turns 'cold' tumors 'hot' to improve cancer immunotherapy

Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns “cold” tumors “hot”. “Cold”, immune-desert tumors are classically immunotherapy-resistant.

13 May 2020

Patients with aggressive form of skin cancer can benefit from new type of immunotherapy

In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery.

27 Apr 2020

Combination therapy boosts the immune system's appetite for cancer

A combination of immunotherapy agents that encourages some immune cells to eat cancer cells and alert others to attack tumors put mice with a deadly type of brain cancer called glioblastoma into long-term remission, a new study led by UT Southwestern scientists suggests.

24 Apr 2020

Researchers uncover how cancer cells don their invisibility cloaks

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results. But exactly how cancer cells turn on this protein was not completely understood.

22 Apr 2020

Tumors commandeer cell death pathway to avoid immune system attack after radiation

Cancer cells avoid an immune system attack after radiation by commandeering a cell signaling pathway that helps dying cells avoid triggering an immune response, a new study led by UTSW scientists suggests.

13 Apr 2020

Study helps predict which ovarian cancer patients will not benefit from immune-PARP combo

In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven't been able to predict which patients won't benefit from the treatment and should explore other options.

19 Mar 2020

Study paves way for identifying ovarian cancer patients who will not benefit from combination therapy

A study suggests it may be possible to identify those who will not benefit from drug combination for advanced ovarian cancer.

19 Mar 2020

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

In the 2020 February 25 issue of Scientific Reports, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that levels of a circulating soluble immune checkpoint protein can be used as a potential marker to predict overall survival in patients with advanced HCC.

9 Mar 2020

Breakthrough technology identifies proteins' nearest neighbors on cell surfaces

When corporate partners in the Princeton Catalysis Initiative sat down two years ago with David MacMillan, they presented him with a biological challenge at the heart of potential cancer medicines and other therapeutics: which proteins on a cell's surface touch each other?

5 Mar 2020

Combination of radiation and immunotherapy shows promise for advanced head and neck cancers

A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma

27 Feb 2020

Biomarkers in blood samples can predict clinical response to immunotherapy in metastatic NSCLC

Non-small cell lung cancer patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.

26 Feb 2020

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer.

21 Feb 2020